MedPath

Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma

Phase 3
Completed
Conditions
Brain and Central Nervous System Tumors
Registration Number
NCT00002840
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, and may be an effective treatment for anaplastic oligodendroglioma. Combining combination chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: Randomized phase III trial to compare radiation therapy with and without combination chemotherapy in patients with resected anaplastic oligodendroglioma.

Detailed Description

OBJECTIVES: I. Compare survival and time to first progression in patients with anaplastic oligodendroglioma treated with radiotherapy with or without adjuvant procarbazine, lomustine, and vincristine (PCV) following surgical resection. II. Investigate the effect of PCV on quality of life and neurologic function in these patients. III. Determine the toxicity of PCV in these patients. IV. Correlate chromosomal lesions (1p and/or 19q, 9p, p53 loss and mutation, amplification of chromosome 7, or loss of chromosome 10) with progression-free and overall survival in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age, extent of resection, performance status, prior surgery, and participating center. Patients are randomized to one of two treatment arms. Arm I: Within 4-6 weeks after surgery, patients undergo radiotherapy over 7 weeks to the residual tumor volume. Arm II: Patients undergo radiotherapy as in arm I, then begin chemotherapy within 4 weeks after the completion of radiotherapy. Patients receive oral lomustine on day 1, oral procarbazine on days 8-21, and vincristine IV on days 8 and 29. Treatment repeats every 6 weeks in stable and responding patients for a total of 6 courses. Patients with disease recurrence may receive 6 additional courses of chemotherapy as above or another modality at the investigator's discretion. Patients are followed every 3 months for 1 year and then every 6 months for survival.

PROJECTED ACCRUAL: A total of 350 patients will be accrued for this study within 4 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
350
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (40)

CHU de la Timone

🇫🇷

Marseille, France

CRLCC Nantes - Atlantique

🇫🇷

Nantes-Saint Herblain, France

Hopital Universitaire Erasme

🇧🇪

Brussels, Belgium

Hopital de Jolimont

🇧🇪

Haine Saint Paul, Belgium

Hopital Pasteur

🇫🇷

Nice, France

Centre Eugene Marquis

🇫🇷

Rennes, France

Kaiser Franz Josef Hospital

🇦🇹

Vienna (Wien), Austria

U.Z. Gasthuisberg

🇧🇪

Leuven, Belgium

Turku University Central Hospital

🇫🇮

Turku, Finland

Centre Hospitalier Regional de Lille

🇫🇷

Lille, France

CHU de Nancy - Hopital Neurologique

🇫🇷

Nancy, France

Centre Antoine Lacassagne

🇫🇷

Nice, France

C.H.R. de Nimes - Hopital Caremeau

🇫🇷

Nimes, France

Institut Gustave Roussy

🇫🇷

Villejuif, France

Neurologische Klinik der Henriettenstiftung

🇩🇪

Hannover, Germany

CHU Pitie-Salpetriere

🇫🇷

Paris, France

National Institute of Neurosurgery

🇭🇺

Budapest, Hungary

Azienda Ospedaliera di Padova

🇮🇹

Padova (Padua), Italy

Klinikum der Friedrich-Schiller Universitaet Jena

🇩🇪

Jena, Germany

Universita di Padova

🇮🇹

Padova, Italy

University Medical Center Nijmegen

🇳🇱

Nijmegen, Netherlands

Academisch Ziekenhuis Groningen

🇳🇱

Groningen, Netherlands

Dr. Bernard Verbeeten Instituut

🇳🇱

Tilburg, Netherlands

Academisch Ziekenhuis Utrecht

🇳🇱

Utrecht, Netherlands

Umea Universitet

🇸🇪

Umea, Sweden

Instituto Portugues de Oncologia de Francisco Gentil

🇵🇹

Lisbon, Portugal

Centre Hospitalier Universitaire Vaudois

🇨🇭

Lausanne, Switzerland

University Hospital of Linkoping

🇸🇪

Linkoping, Sweden

Queen's Medical Centre

🇬🇧

Nottingham, England, United Kingdom

Nottingham General Hospital

🇬🇧

Nottingham, England, United Kingdom

Nottingham City Hospital NHS Trust

🇬🇧

Nottingham, England, United Kingdom

Royal Marsden Hospital

🇬🇧

Sutton, England, United Kingdom

Southampton General Hospital

🇬🇧

Southampton, England, United Kingdom

Academisch Ziekenhuis der Vrije Universiteit Brussel

🇧🇪

Brussels (Bruxelles), Belgium

Vrije Universiteit Medisch Centrum

🇳🇱

Amsterdam, Netherlands

Academisch Medisch Centrum

🇳🇱

Amsterdam, Netherlands

Medisch Centrum Haaglanden

🇳🇱

's-Gravenhage (Den Haag, The Hague), Netherlands

Rotterdam Cancer Institute

🇳🇱

Rotterdam, Netherlands

St. Elisabeth Ziekenhuis

🇳🇱

Tilburg, Netherlands

Royal South Hants Hospital

🇬🇧

Southampton, England, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath